Bone

Soluble FGFR-3 as potential therapy for achondroplasia

    French researchers have developed a recombinant protein therapeutic approach, based on a soluble form of human fibroblast growth factor receptor 3 (sFGFR-3), to treat mice with abnormal bone development caused by achondroplasia. This genetic disorder, which is characterized by short stature, is caused by a single point mutation in the gene FGFR3, which leads to prolonged receptor activation upon FGF binding. sFGFR-3 prevents ligand binding to the mutant receptor, thereby preventing excessive intracellular signalling and rescuing the symptoms of achondroplasia.

    References

    1. 1

      Garcia, S. et al. Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice. Sci. Transl. Med. 5, 203ra124 (2013)

      PubMed  Google Scholar 

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Soluble FGFR-3 as potential therapy for achondroplasia. Nat Rev Endocrinol 9, 692 (2013). https://doi.org/10.1038/nrendo.2013.194

    Download citation

    Search

    Nature Briefing

    Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

    Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing